Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 20/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 18/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 17/20 | 0.57 |
| ▸ | HRH1 | P35367 | 2/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7212035 | 0.86 | ADRA1A (0.59) | ADRA1AADRA1BADRA1DHRH1ADRA2A | |
| SCHEMBL5662332 | 0.81 | ADRA1A (0.55) | ADRA1AADRA1BADRA1DHRH1 | |
| SCHEMBL5660423 | 0.81 | ADRA1A (0.55) | ADRA1AADRA1BADRA1DHRH1 | |
| SCHEMBL7213199 | 0.79 | ADRA1A (0.63) | ADRA1AADRA1BADRA1DHRH1 | |
| SCHEMBL7226013 | 0.76 | ADRA1A (0.66) | ADRA1AADRA1BADRA1DHRH1ADRA2A | |
| SCHEMBL7212013 | 0.76 | ADRA1A (0.55) | ADRA1AADRA1BADRA1DHRH1 | |
| SCHEMBL7213122 | 0.76 | ADRA1A (0.59) | ADRA1AADRA1BADRA1DHRH1 | |
| SCHEMBL5662392 | 0.75 | MCHR1 (0.57) | ADRA1AADRA1BADRA1DHRH1 | |
| SCHEMBL7747511 | 0.75 | ADRA1A (0.57) | ADRA1AADRA1BADRA1DHRH1ADRA2A | |
| SCHEMBL7747513 | 0.75 | ADRA1A (0.57) | ADRA1AADRA1BADRA1DHRH1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |